Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes

Table 5

Subgroup analyses of baseline and 12-month BCVA levels and CRT on OCT images by disease.

	DME; ( eyes)	BRVO; ( eyes)	CRVO; ( eyes)	Irvine-Gass; ( eyes)	value
BCVA
Baseline Snellen VA	0.13 (0.01–0.67)	0.20 (0.00–1.00)	0.06 (0.01–0.50)	0.20 (0.13–0.67)	0.215
12-month Snellen VA	0.37 (0.01–1.00)	0.33 (0.03–0.80)	0.04 (0.01–0.67)	0.67 (0.67–1.00)	0.007
OCT
Baseline CRT (µm)	444 (214–746)	421 (302–674)	693 (415–840)	686 (313–777)	0.058
12-month CRT (µm)	264 (164–702)	289 (203–741)	367 (213–700)	220 (216–244)	0.15

Kruskal-Wallis for independent samples.
Data are expressed as the mean (minimum–maximum).
OCT, optical coherence tomography; BCVA, best-corrected visual acuity; DME, diabetic macular edema; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; CRT, central retinal thickness.